Cognetivity Neurosciences Ltd. confirmed that its Integrated Cognitive Assessment software has been approved as a CE-marked medical device. The announcement follows Cognetivity's registration of the ICA with the UK's Medicines and Healthcare products Regulatory Agency last month and enables the ICA to be used clinically across Europe.Regulatory approval grants the ICA a CE mark, demonstrating conformity with EU medical device safety and performance requirements. It permits the ICA to be sold as a medical product in the UK and throughout the European Economic Area, the population of which exceeds 500 million people, with one in five over the age of 65. As such, it represents a major milestone in the company's development and paves the way for its plans to obtain regulatory approval in other jurisdictions, including the USA, Canada and China.